Facial tissue allograft transplantation

Area of Science:

• Transplantation immunology
• Immunosuppression strategies
• Chimerism research

Background:

• Investigating functional tolerance across major histocompatibility complex (MHC) barriers is crucial for advancing transplantation.
• Hemifacial allograft transplantation models provide a platform to study immune responses to foreign tissue.
• Understanding the mechanisms underlying transplant tolerance can lead to improved patient outcomes.

Purpose of the Study:

• To investigate the rationale for developing functional tolerance across an MHC barrier using a hemifacial allograft transplant model.
• To evaluate the efficacy of Cyclosporine A (CsA) monotherapy in inducing and maintaining tolerance in allograft recipients.
• To determine the association between donor-specific chimerism and functional tolerance in hemifacial allografts.

Main Methods:

• Hemifacial allograft transplantations were performed in Lewis rats using semiallogenic (LBN) and fully allogenic (ACI) donors.
• Recipients in experimental groups received CsA monotherapy at varying dosages and durations.
• Graft rejection was monitored daily, and flow cytometry and mixed lymphocyte reaction (MLR) assays were used to assess chimerism and immune responses.

Main Results:

• All untreated allografts were rejected within 5-8 days, while isografts survived indefinitely.
• 83% of LBN and 67% of ACI hemifacial allograft recipients showed no signs of rejection up to 270 and 200 days, respectively.
• Flow cytometry confirmed donor-specific chimerism in T- and B-cell subpopulations in tolerant recipients, with suppressed MLR responses.

Conclusions:

• CsA monotherapy can induce functional tolerance in hemifacial allograft transplants across an MHC barrier.
• Donor-specific chimerism in T- and B-cell subpopulations is associated with the induction and maintenance of this functional tolerance.
• This study provides evidence for a potential strategy to overcome MHC barriers in transplantation.